Activist Group Escalates Proxy Contest, Citing 91% Share Price Collapse and Governance Failures
Summary
An activist shareholder group has filed additional proxy materials, detailing allegations of severe mismanagement, significant share price decline, and governance failures, urging shareholders to vote for their three director nominees at the upcoming Annual Meeting.
Key Events
-
Proxy Contest Intensifies
The 'Concerned Vaxart Stockholders' group, owning 1,515,343 shares, is actively soliciting votes for three independent director nominees (Daniel P. Houle, Mark Silverberg, Matthew M. Wallace) at the July 16, 2026 Annual Meeting.
-
Allegations of Shareholder Value Destruction
The activist group highlights a 91% share price collapse over five years and $343 million in accumulated losses since 2020, significantly underperforming sector and broader market indices.
-
Criticism of Dilutive Offering
The group criticizes management for executing a 50 million share offering at $0.80 per share on June 13, 2024, just hours after announcing a $453 million BARDA award, effectively diluting shareholders before the market could react positively to the funding.
-
Lack of Transparency Regarding Director Investigation
Allegations include the Board's failure to disclose a federal insider-trading investigation into former director Robert A. Yedid, who later pled guilty, instead announcing his resignation for 'personal reasons'.
Analysis
An activist shareholder group, "Concerned Vaxart Stockholders," has filed additional definitive proxy materials, intensifying its campaign to elect three new directors at the upcoming July 16, 2026 Annual Meeting. The group, owning 1.5 million shares, alleges severe mismanagement, including a 91% share price decline over five years, $343 million in losses, significant shareholder dilution following a major BARDA award, concealment of a director's insider trading investigation, and excessive executive compensation despite shareholder opposition. This filing is a direct appeal to shareholders, detailing specific grievances and urging a vote for their nominees to address what they describe as a pattern of ignoring stockholder will.
At the time of this filing, VXRT was trading at $0.60 on OTC in the Life Sciences sector, with a market capitalization of approximately $144.9M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.